Imperial College London


Faculty of MedicineSchool of Public Health

Professor of Global Health



+44 (0)20 7594 1150timothy.hallett




Norfolk PlaceSt Mary's Campus






BibTex format

author = {Christian, S and Anna, B and Dobromir, D and Blythe, A and Paul, R and Hallett, T and Andrew, P and Linda-Gail, B and Helen, R and Glenda, G},
doi = {10.1016/j.vaccine.2019.02.073},
journal = {Vaccine},
pages = {2258--2267},
title = {Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine tegimen in South Africa},
url = {},
volume = {37},
year = {2019}

RIS format (EndNote, RefMan)

AB - BackgroundRV144 is to date the only HIV vaccine trial to demonstrate efficacy, albeit rapidly waning over time. The HVTN 702 trial is currently evaluating in South Africa a similar vaccine formulation to that of RV144 for subtype C HIV with additional boosters (pox-protein regimen). Using a detailed stochastic individual-based network model of disease transmission calibrated to the HIV epidemic, we investigate population-level impact and maximum cost of an HIV vaccine to remain cost-effective.MethodsConsistent with the original pox-protein regimen, we model a primary series of five vaccinations meeting the goal of 50% cumulative efficacy 24months after the first dose and include two-yearly boosters that maintain durable efficacy over 10years. We simulate vaccination programs in South Africa starting in 2027 under various vaccine targeting and HIV treatment and prevention assumptions.ResultsOur analysis shows that this partially effective vaccine could prevent, at catch-up vaccination with 60% coverage, up to 941,000 (15.6%) new infections between 2027 and 2047 assuming current trends of antiretroviral treatment. An impact of up to 697,000 (11.5%) infections prevented could be achieved by targeting age cohorts of highest incidence. Economic evaluation indicates that, if treatment scale-up was achieved, vaccination could be cost-effective at a total cost of less than $385 and $62 per 10-year series (cost-effectiveness thresholds of $5,691 and $750).ConclusionsWhile a partially effective, rapidly waning vaccine could help to prevent HIV infections, it will not eliminate HIV as a public health priority in sub-Saharan Africa. Vaccination is expected to be most effective under targeted delivery to age groups of highest HIV incidence. Awaiting results of trial, the introduction of vaccination should go in parallel with continued innovation in HIV prevention, including studies to determine the costs of delivery and feasibility and further research into products with great
AU - Christian,S
AU - Anna,B
AU - Dobromir,D
AU - Blythe,A
AU - Paul,R
AU - Hallett,T
AU - Andrew,P
AU - Linda-Gail,B
AU - Helen,R
AU - Glenda,G
DO - 10.1016/j.vaccine.2019.02.073
EP - 2267
PY - 2019///
SN - 0264-410X
SP - 2258
TI - Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine tegimen in South Africa
T2 - Vaccine
UR -
UR -
VL - 37
ER -